Trial Profile
Effects of SGLT2 inhibitor patients with type 2 diabetes under treatment with DPP-4 inhibitor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2018
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Anagliptin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Linagliptin (Primary) ; Luseogliflozin (Primary) ; Sitagliptin (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jan 2018 New trial record
- 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation